Mielodiszplasztikus szindróma (MDS): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

6+ intézményből 6, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

  Syntrix Biosystems, Inc.· Auburn, Egyesült Államok· 406 500 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · DP2

  Single-molecule, Single-cell profiling of chromatin protein-protein interactions.

  Van Andel Research Institute· Grand Rapids, Egyesült Államok· 912 000 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIDDK · R01

  Role of IL-1 beta signaling in stress erythropoiesis

  Pennsylvania State University, the· University Park, Egyesült Államok· 641 869 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NHLBI · R01

  Mechanisms underlying germline predisposition to clonal hematopoiesis

  Albert Einstein College of Medicine· Bronx, Egyesült Államok· 693 151 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NHGRI · R01

  A single-cell multiomics platform for studying genome structure and function

  University of Washington· Seattle, Egyesült Államok· 796 114 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility (DiagMDS)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Görögország· EU contribution 1 322 640 EUR· until 2030. szept.· 9 countries

• European Commission (Horizon 2020) · ERC-COG

  Identifying spatial determinants of immune cell fate commitment (ImmuNiche)

  Julius-Maximilians-Universitat Wurzburg· Wuerzburg, Németország· EU contribution 1 997 500 EUR· until 2026. dec.

7 of 170 running projects, newest first. Listed amounts together: 121,5 M USD + 3,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Frissítve: 2026. okt. 20.

  “The trial closed early due to changes in support for the study drug.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Frissítve: 2026. jan. 13.

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Frissítve: 2026. jan. 13.

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Frissítve: 2025. okt. 16.

  “Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

  NCT03940352· Novartis Pharmaceuticals· Frissítve: 2025. okt. 10.

  “Business decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Frissítve: 2024. ápr. 11.

  “waiting for update from Study Lead”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Forrás

• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Forrás

• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Forrás

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Forrás

• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.

  Front Immunol, 2026. júl.

• Non-invasive differentiation between aplastic anemia and myelodysplastic syndromes based on an 8-feature lightGBM model: A multicenter external validation study.

  Curr Res Transl Med, 2026. júl.

• Evaluation of the Usefulness of Machine Learning and Artificial Intelligence on Hyperspectral Images in the Diagnosis of Myelodysplastic Syndrome.

  J Biophotonics, 2026. júl.

• Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case-Control Study.

  Muscle Nerve, 2026. márc.

• Interpretable Machine Learning to Decipher Myelodysplastic Syndrome-Associated Alterations of the Extracellular Matrix by Time-of-Flight Secondary Ion Mass Spectrometry.

  J Am Soc Mass Spectrom, 2026. márc.

• Review of flow cytometry findings and associated scoring approaches for identifying myelodysplastic syndrome and the future role of machine learning in improving the diagnostic algorithm.

  Am J Clin Pathol, 2026. jan.

• Prediction of myeloid malignant cells in Fanconi anemia using machine learning.

  PLoS One, 2026. jan.

• Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

  JCO Clin Cancer Inform, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.